Chlorpromazine for schizophrenia: A cochrane systematic review of 50 years of randomised controlled trials

Clive Elliott Adams*, John Rathbone, Ben Thornley, Mike Clarke, Jo Borrill, Kristian Wahlbeck, A. George Awad

*Corresponding author for this work

Research output: Contribution to journalReview articleResearchpeer-review

40 Citations (Scopus)

Abstract

Background: Chlorpromazine (CPZ) remains one of the most common drugs used for people with schizophrenia worldwide, and a benchmark against which other treatments can be evaluated. Quantitative reviews are rare; this one evaluates the effects of chlorpromazine in the treatment of schizophrenia in comparison with placebo. Methods: We sought all relevant randomised controlled trials (RCT) comparing chlorpromazine to placebo by electronic and reference searching, and by contacting trial authors and the pharmaceutical industry. Data were extracted from selected trials and, where possible, synthesised and random effects relative risk (RR), the number needed to treat (NNT) and their 95% confidence intervals (CI) calculated. Results: Fifty RCTs from 1955-2000 were included with 5276 people randomised to CPZ or placebo. They constitute 2008 person-years spent in trials. Meta-analysis of these trials showed that chlorpromazine promotes a global improvement (n=1121, 13 RCTs, RR 0.76 CI 0.7 to 0.9, NNT 7 CI 5 to 10), although a considerable placebo response is also seen. People allocated to chlorpromazine tended not to leave trials early in both the short (n=945, 16 RCTs, RR 0.74 CI 0.5 to 1.1) and medium term (n=1861, 25 RCTs, RR 0.79 CI 0.6 to 1.1). There were, however, many adverse effects. Chlorpromazine is sedating (n=1242, 18 RCTs, RR 2.3 CI 1.7 to 3.1, NNH 6 CI 5 to 8), increases a person's chances of experiencing acute movement disorders, Parkinsonism and causes low blood pressure with dizziness and dry mouth. Conclusions: It is understandable why the World Health Organization (WHO) have endorsed and included chlorpromazine in their list of essential drugs for use in schizophrenia. Low- and middle-income countries may have more complete evidence upon which to base their practice compared with richer nations using recent innovations.

Original languageEnglish
Article number15
JournalBMC Medicine
Volume3
DOIs
Publication statusPublished - 17 Oct 2005
Externally publishedYes

Fingerprint

Dive into the research topics of 'Chlorpromazine for schizophrenia: A cochrane systematic review of 50 years of randomised controlled trials'. Together they form a unique fingerprint.

Cite this